Delivery Order SPE2DB24D3013-SPE2DB25FFPBB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of the contractor's pharmaceutical supply relationship with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract represents a non-set-aside award made through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order valued at $3,280.00 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract (no set-aside used) was executed on August 12, 2025, with an ultimate completion date of August 13, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's extensive...
- The Defense Logistics Agency awarded a $33,295.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units), with an ultimate completion date of August 19, 2025. This non-set-aside contract represents a competitive award to the pharmaceutical distributor, with performance to be conducted at the company's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a prescription medication used to treat inflammatory conditions, and...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $5,350.64 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a $4,455.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units), with an ultimate completion date of July 21, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. The delivery order represents a...
- The Defense Logistics Agency awarded a $7,102.01 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract. The award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where the vendor maintains its...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPBBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,632.60 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The delivery will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This order exemplifies the company's role as a critical pharmaceutical supplier under the DLA Troop Support Medical prime vendor contract, which enables comprehensive global pharmaceutical support for military healthcare programs. XELJANZ XR is a brand-name immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of therapeutic domains covered under the underlying indefinite delivery vehicle that encompasses specialty medications, generic drugs, vaccines, and related medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/5/25 |